Wall Street brokerages forecast that Crispr Therapeutics AG (NASDAQ:CRSP) will announce sales of $1.25 million for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Crispr Therapeutics’ earnings. The highest sales estimate is $2.00 million and the lowest is $500,000.00. Crispr Therapeutics reported sales of $1.36 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 8.1%. The business is expected to issue its next quarterly earnings report on Tuesday, May 14th.
On average, analysts expect that Crispr Therapeutics will report full year sales of $25.82 million for the current fiscal year, with estimates ranging from $4.00 million to $91.10 million. For the next year, analysts expect that the company will report sales of $42.43 million, with estimates ranging from $8.00 million to $109.30 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, February 25th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The company had revenue of $0.10 million during the quarter, compared to analyst estimates of $1.56 million. Crispr Therapeutics had a negative net margin of 5,281.08% and a negative return on equity of 48.35%. Crispr Therapeutics’s revenue for the quarter was down 99.7% compared to the same quarter last year.
Shares of CRSP stock traded up $0.79 on Wednesday, hitting $35.72. The company had a trading volume of 444,861 shares, compared to its average volume of 760,790. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -10.38 and a beta of 3.13. Crispr Therapeutics has a twelve month low of $22.22 and a twelve month high of $73.90.
In other news, President Rodger Novak sold 85,220 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $40.40, for a total value of $3,442,888.00. Following the transaction, the president now owns 1,024,534 shares in the company, valued at $41,391,173.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 126,003 shares of company stock worth $4,989,303 in the last 90 days. Corporate insiders own 37.70% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. Ontario Teachers Pension Plan Board purchased a new stake in shares of Crispr Therapeutics during the fourth quarter valued at approximately $16,598,000. EcoR1 Capital LLC purchased a new stake in shares of Crispr Therapeutics during the third quarter valued at approximately $22,175,000. Credit Suisse AG increased its position in shares of Crispr Therapeutics by 56.0% during the third quarter. Credit Suisse AG now owns 596,052 shares of the company’s stock valued at $26,435,000 after acquiring an additional 213,988 shares during the last quarter. Laurion Capital Management LP purchased a new stake in shares of Crispr Therapeutics during the third quarter valued at approximately $7,660,000. Finally, Capital International Investors purchased a new stake in shares of Crispr Therapeutics during the third quarter valued at approximately $6,120,000. Institutional investors own 42.23% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Featured Article: How to interpret a stock’s beta number
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.